IQVIA (IQV) Stock: Buy, Sell, or Hold?
IQV - IQVIA Holdings Inc.
$260.72
-8.13 (-3.02%)
âŧ
5d:
-5.2%
30d:
+0.92%
90d:
+25.93%
WAIT
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Oct 27, 2026
24d
Get Alerted When IQV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: IQV is fairly priced but lacks strong directional signals. At 6.8% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: IQV is fairly priced but lacks strong directional signals. At 6.8% expected growth, valuation appears stretched. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$311.32
Based on 7.8% avg growth
INTRINSIC VALUE TODAY
$193.30
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IQV is currently trading at $260.72, which is considered slightly high relative to its 30-day fair value range of $260.40 to $270.37. From a valuation perspective, the stock is trading at a premium (Forward PE: 18.0) compared to its historical average (14.8). At these levels, the market is pricing in 6.8% annual earnings growth.
Technical Outlook: Technically, IQV is in a strong uptrend. The price is currently testing key support at $259.31. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: IQV scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $288.74 (+10.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IQV is in a strong uptrend. The price is currently testing key support at $259.31. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.0% recently.
Market Sentiment: IQV scores 36/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $288.74 (+10.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$260.40 -
$270.37
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
39.0%
Protect Your Profits
Holding IQV? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Weak technical setup (36/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.0%)
- BULLISH: Trading below Wall St target ($288.74)
- BULLISH: Expecting earnings turnaround to 6.8% growth with 8.7% revenue growth
- WARNING: Composite score 52/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$260.40 -
$270.37
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$259.31
Resistance Level
$277.40
Current Trend
Strong Uptrend
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
18.02
Wall Street Target
$288.74
(+10.7%)
Revenue Growth (YoY)
8.7%
Earnings Growth (YoY)
-0.6%
Profit Margin
8.1%
Valuation Premium vs History
+6.8% premium
PE vs Historical
18.0 vs 14.8
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+6.8%
(market-implied from PE analysis)
1-Year Target
$278.45
(+7%)
2-Year Target
$297.38
(+14%)
3-Year Target
$317.61
(+22%)
3-Yr Target (if PE normalizes)
(PE: 18â15)
PE COMPRESSION
$260.92
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 11.6%)
$410.56
(+58%)
Base:
(SPY PE: 18.0, Growth: 11.6%)
$362.57
(+39%)
Bear:
(PE: 14.8, Growth: 11.6%)
$297.86
(+14%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (33x PE), but valuation improves significantly next year (18x PE) as earnings recover.
Trailing PE: 33.16 | Current EPS (TTM): $8.04
Bull Case
$527.81
(+102%)
Analyst growth 80.0%, PE expands to 36.5
Base Case
$479.83
(+84%)
Market implied 80.0%, PE stable at 33.2
Bear Case
$181.27
(-31%)
Severe decline -20.0%, PE contracts to 28.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 02, 2026 3:46 AM ET
Data refreshes hourly during market hours. Next update: 4:46 AM
Data refreshes hourly during market hours. Next update: 4:46 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IQV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher ScientificâĻ |
STRONG BUY
31 analysts |
$653 | 43 HOLD |
|
EXAS
EXACT Sciences CorporatiâĻ |
STRONG BUY
26 analysts |
$106 | 52 HOLD |
|
DHR
Danaher Corporation |
STRONG BUY
25 analysts |
$231 | 48 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
23 analysts |
$196 | 46 HOLD |
|
LH
Laboratory Corporation oâĻ |
STRONG BUY
20 analysts |
$345 | 65 BUY |
Advanced IQV Option Strategies
Professional options setups generated by AI based on today's IQV price and gamma walls.
